Viral Envelope Glycoprotein

A viral envelope glycoprotein is a membrane-anchored oligomeric surface protein embedded in the lipid bilayer of an enveloped virus that executes two sequential biophysical functions: binding to specific host-cell receptors and catalyzing the fusion of the viral envelope with a cellular membrane to deliver the viral genome into the cytoplasm. Because merging two hydrated phospholipid bilayers requires overcoming an electrostatic and hydration repulsive barrier of approximately 40 to 50 kcal mol⁻¹, viral fusion glycoproteins fold during biosynthesis into a kinetically trapped, high-energy metastable prefusion conformation. Upon encountering a specific molecular trigger—such as host receptor engagement, endosomal acidification (low pH), or proteolytic cleavage—the glycoprotein undergoes an irreversible, spring-loaded conformational rearrangement into a low-energy postfusion hairpin state, using the released free energy to pull the viral and cellular membranes together through a hemifusion stalk intermediate into an expanding fusion pore.

Because envelope glycoproteins are the primary (and often sole) viral antigens exposed on the exterior of intact virions, they are the principal target of host neutralizing antibodies, monoclonal antibody therapy, and modern vaccines. Consequently, viral glycoproteins evolve under intense dual selection pressure: maintaining structural conservation within their core fusion machinery while accumulating rapid amino-acid mutations and dense N- and O-linked carbohydrate glycan shields across their solvent-exposed receptor-binding caps.

Comparative X-ray crystallography and cryo-electron microscopy across diverse viral families classify envelope fusion glycoproteins into three primary structural classes based on their secondary-structure architecture in the prefusion and postfusion states:

Proteolytic Maturation and Two-Step Endosomal Priming

Class I viral glycoproteins are synthesized in the host endoplasmic reticulum as single-chain precursor polypeptides (such as GP₀ in Orthoebolavirus, HA0 in influenza, or gp160 in HIV-1) that assemble into non-covalent homotrimers and undergo extensive co-translational N-linked glycosylation. During transit through the trans-Golgi network, host proprotein convertases (most commonly furin) cleave the precursor at a polybasic consensus motif (R-X-K/R-R) into two subunits that remain associated via non-covalent interactions or an inter-subunit disulfide bond:

1. The Surface / Receptor-Binding Subunit (GP₁, HA1, S1, gp120): Forms the distal globular head and glycan cap that mediates initial host-cell attachment and shields the underlying fusion peptide.
2. The Transmembrane / Fusion Subunit (GP₂, HA2, S2, gp41): Anchors the trimer into the viral lipid envelope via a C-terminal transmembrane helix and contains the hydrophobic fusion peptide (or internal fusion loop) along with two amphipathic α-helical heptad repeat regions (HR1 and HR2).

In filoviruses such as Zaire ebolavirus and Bundibugyo ebolavirus, furin cleavage in the producer cell is followed by a second, mandatory proteolytic priming step inside the target cell's late endosome: host cysteine proteases (cathepsin B and cathepsin L) remove the bulky O-glycosylated mucin-like domain (MLD) and outer glycan cap (~60% of the GP₁ mass), unmasking the recessed receptor-binding crest so it can engage Domain C of Niemann–Pick C1 (NPC1).

The Extended Pre-Hairpin Intermediate and Six-Helix Bundle (6HB) Zippering

Once the primed GP₁ subunit binds its receptor at endosomal pH, the clamp holding the metastable GP₂ fusion subunit is released, initiating a three-stage mechanical cascade:

1. Pre-Hairpin Extension and Hydrophobic Insertion: The segmented HR1 helices snap together into a continuous, elongated triple-stranded α-helical coiled-coil, propelling the hydrophobic internal fusion loop (stabilized by a disulfide bond at its base and containing a conserved aromatic–hydrophobic W-I-P-Y-F patch) ~100 Å upward to insert into the target cellular membrane. At this transient extended pre-hairpin intermediate stage, the glycoprotein physically bridges both the viral and host membranes.
2. Fold-Back and Six-Helix Bundle Formation: The C-terminal HR2 helices pack antiparallel into the hydrophobic grooves along the exterior of the central trimeric HR1 coiled-coil, folding the molecule back onto itself like a jackknife to form a thermostable six-helix bundle (6HB, or trimer-of-hairpins) with a melting temperature T_moften exceeding 85–90 °C.
3. Hemifusion Stalk and Fusion Pore Expansion: Because the N-terminal fusion loop is embedded in the host membrane while the C-terminal transmembrane domain is anchored in the viral envelope, zippering of the 6HB forces the two apposed bilayers within <1.5 nm, inducing outer-leaflet lipid mixing (hemifusion stalk), inner-leaflet merging, and opening of a transmembrane fusion pore through which the viral ribonucleoprotein core enters the cytosol.

Decoy Antigens, Mucin Domains, and Conserved Stalk Epitopes

Enveloped viruses deploy multiple structural adaptations on their glycoproteins to evade humoral immunity:

• Dense Carbohydrate Shielding and Mucin-Like Domains: Host-derived N- and O-linked oligosaccharides coat the outer surface of viral glycoproteins, appearing immunologically "self" and sterically occluding underlying polypeptide epitopes. In Orthoebolavirus, each GP₁ monomer carries a heavily O-glycosylated mucin-like domain (~150 amino acids) and glycan cap that sit atop the trimer chalice; these outer domains diverge by 35% to 45% in amino-acid sequence between Zaire, Sudan, and Bundibugyo ebolavirus, explaining why antibodies directed at the outer cap are strictly species-specific.
• Antigenic Subversion via Secreted Glycoprotein (sGP): In Orthoebolavirus, ~70–80% of GP gene transcripts are unedited and encode a non-structural, dimeric secreted glycoprotein (sGP) that shares the N-terminal 295 residues of GP₁, acting as an extracellular soluble decoy that absorbs glycan-cap antibodies in the bloodstream.
• Vulnerability of the Conserved Chalice Base and Internal Fusion Loop: In contrast to the hypervariable apex, the lower glycoprotein base, the internal fusion loop, and the HR1/HR2 stalk must preserve precise biophysical geometries to execute membrane fusion and therefore share >80–90% sequence identity across divergent species. Broadly neutralizing monoclonal antibody therapy cocktails (such as pan-ebolavirus MBP134 or influenza stem antibodies) target this conserved base/fusion-loop interface, mechanically locking the prefusion trimer and preventing pre-hairpin extension across multiple viral species.

Prefusion Stabilization in Vaccine Engineering

Because native Class I viral glycoproteins are metastable, purified recombinant subunits or viral-vector antigens can spontaneously flip into their low-energy postfusion 6HB conformation before encountering B cells, displaying non-neutralizing postfusion surfaces rather than the protective prefusion epitopes present on infectious virions. Structure-based vaccine design pioneered by Barney Graham, Jason McLellan, and Peter Kwong overcomes this instability by introducing proline substitutions (such as the I559P mutation in HIV-1 SOSIP trimers, disulfide/cavity-filling DS-Cav1 in RSV F, and 2P / HexaPro at the hinge loop between the central helix and HR1 in coronavirus Spike proteins), sterically blocking helix straightening and locking the immunogen in its native prefusion trimer state.

Why do Class I and Class II viral glycoproteins converge on a hairpin postfusion state despite having completely different folds?

Although Class I glycoproteins are built from α-helical coiled-coils and Class II glycoproteins are built from β-sheet domains, both classes solve the same thermodynamic problem: pulling two separate membranes together. In both architectures, the extended intermediate places the N-terminal fusion peptide/loop in the host membrane and the C-terminal transmembrane anchor in the viral membrane; folding the polypeptide chain back into a hairpin brings the N- and C-termini to the same end of a rigid rod, mechanically drawing the two lipid bilayers into contact.

Why are Class III rhabdovirus G proteins reversible with pH whereas Class I fusion proteins are irreversible?

In Class I glycoproteins (such as filovirus GP_1,2 or influenza HA), proteolytic cleavage removes a covalent constraint and allows the transition to a deep thermodynamic minimum (the 6HB) separated by a massive kinetic barrier, making refolding irreversible. In contrast, the Class III G glycoprotein of vesicular stomatitis virus (VSV) and rabies virus is never proteolytically cleaved; its prefusion and postfusion states exist in a pH-dependent thermodynamic equilibrium controlled by protonation of conserved histidine residues, allowing the protein to recover its native prefusion conformation if returned to neutral pH prior to membrane insertion.

How do fusion inhibitor peptides such as enfuvirtide block viral entry?

Synthetic peptides modeled on the C-terminal heptad repeat (HR2, such as the 36-amino-acid HIV-1 drug enfuvirtide/T-20 or cholesterol-conjugated endosomal peptides for paramyxoviruses and filoviruses) bind to the exposed hydrophobic grooves of the N-terminal HR1 coiled-coil during the transient extended pre-hairpin intermediate stage. By occupying the HR1 grooves, the exogenous peptide prevents the virus's own HR2 helices from folding back to complete the six-helix bundle, arresting membrane fusion before lipid mixing can occur.

1. Harrison, S. C. (2015). Viral membrane fusion. Virology, 479–480, 498–507. https://doi.org/10.1016/j.virol.2015.03.043
2. Lee, J. E., Fusco, M. L., Hessell, A. J., Oswald, W. B., Burton, D. R., & Saphire, E. O. (2008). Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature, 454(7201), 177–182. https://doi.org/10.1038/nature07082
3. Rey, F. A., & Lok, S.-M. (2018). Common features of enveloped viruses and implications for immunogen design. Cell, 172(6), 1319–1334. https://doi.org/10.1016/j.cell.2018.02.054
4. Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019). Structure-based vaccine antigen design. Annual Review of Medicine, 70, 91–104. https://doi.org/10.1146/annurev-med-121217-094234